Can cannabinoids and particularly CBD be an adjunct therapy for Colorectal Adenocarcinoma?
Adenocarcinoma is the most common type of colorectal cancer.
The inhibition of the cancer cell proliferation and induction of apoptosis in cancer cells by CB1 and CB2 activation has been reported. A recent study by Cerretani et al., demonstrated that CBD-induced cytotoxicity in HT-29 cells occurs through a CB1 and CB2 receptor-independent mechanism.
[caption id="attachment_1612" align="aligncenter" width="535"] Cytotoxic effects on the cellular viability of HT-29 cells exposed to IC50 of THC, CBD, and CB83 in the presence of AM251 (CB1 antagonist) 1μM and AM630 (CB2 antagonist) 1 μM. The results are expressed as % of control. Data are representative of three independent experiments. Data were statistically evaluated. * p < 0.05 and ** p < 0.01 vs. control.
Source: Int. J. Mol. Sci. 2020, 21(15), 5533[/caption]
No sign of oxidative stress was evident when CB1 or CB2 agonists were used. CBD increased ROS production, which led to apoptotic cell death.
You can learn more here.